Comparative Pharmacology
Head-to-head clinical analysis: METHADONE HYDROCHLORIDE versus METHADOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHADONE HYDROCHLORIDE versus METHADOSE.
METHADONE HYDROCHLORIDE vs METHADOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mu-opioid receptor agonist; also NMDA receptor antagonist and serotonin/norepinephrine reuptake inhibitor.
Methadone is a mu-opioid receptor agonist; it also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake, contributing to its analgesic and detoxification effects. It has a long half-life and reduces opioid craving and withdrawal symptoms.
Oral: 20-30 mg daily for induction, then 20-120 mg daily for maintenance; IV: 2.5-10 mg every 8-12 hours for acute pain, titrated; IM/SC: same as IV. Frequency: daily for maintenance, every 8-12 hours for pain.
Oral: 20-40 mg once daily, titrated to effect; for opioid dependence, typical maintenance 80-120 mg/day. IV: 2.5-10 mg every 8-12 hours.
None Documented
None Documented
Terminal half-life 24-36 hours (range 13-50 hours) for active l-isomer; clinical context: once-daily dosing possible but cautious due to prolonged QT interval risk.
Terminal elimination half-life range: 8–59 hours (mean ~20–35 hours). In chronic use, half-life may increase due to accumulation. Context: The long half-life supports once-daily dosing for opioid dependence but requires careful titration to avoid accumulation.
Renal (80-90% as methadone and metabolites; ~30% unchanged), biliary/fecal (minor ~10%)
Primarily renal (approximately 80%) as inactive metabolites, with about 20% eliminated via feces. Less than 10% excreted unchanged.
Category D/X
Category C
Opioid Agonist
Opioid Agonist